Dermata Therapeutics Stock Forward View - Simple Moving Average
| DRMA Stock | USD 2.02 0.23 10.22% |
Dermata Stock outlook is based on your current time horizon. Investors can use this forecasting interface to forecast Dermata Therapeutics stock prices and determine the direction of Dermata Therapeutics's future trends based on various well-known forecasting models. We suggest always using this module together with an analysis of Dermata Therapeutics' historical fundamentals, such as revenue growth or operating cash flow patterns.
At this time, the RSI of Dermata Therapeutics' share price is approaching 45 suggesting that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Dermata Therapeutics, making its price go up or down. Momentum 45
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter (1.50) | EPS Estimate Current Year (8.00) | EPS Estimate Next Year (3.01) | Wall Street Target Price 10 | EPS Estimate Current Quarter (1.59) |
Using Dermata Therapeutics hype-based prediction, you can estimate the value of Dermata Therapeutics from the perspective of Dermata Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Moving Average forecasted value of Dermata Therapeutics on the next trading day is expected to be 2.02 with a mean absolute deviation of 0.18 and the sum of the absolute errors of 10.57. Dermata Therapeutics after-hype prediction price | USD 1.98 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Dermata Therapeutics to cross-verify your projections. Dermata Therapeutics Additional Predictive Modules
Most predictive techniques to examine Dermata price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Dermata using various technical indicators. When you analyze Dermata charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Dermata Therapeutics Simple Moving Average Price Forecast For the 4th of February
Given 90 days horizon, the Simple Moving Average forecasted value of Dermata Therapeutics on the next trading day is expected to be 2.02 with a mean absolute deviation of 0.18, mean absolute percentage error of 0.05, and the sum of the absolute errors of 10.57.Please note that although there have been many attempts to predict Dermata Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Dermata Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Dermata Therapeutics Stock Forecast Pattern
| Backtest Dermata Therapeutics | Dermata Therapeutics Price Prediction | Research Analysis |
Dermata Therapeutics Forecasted Value
In the context of forecasting Dermata Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Dermata Therapeutics' downside and upside margins for the forecasting period are 0.02 and 12.01, respectively. We have considered Dermata Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Moving Average forecasting method's relative quality and the estimations of the prediction error of Dermata Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Dermata Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 111.4963 |
| Bias | Arithmetic mean of the errors | 0.0255 |
| MAD | Mean absolute deviation | 0.1792 |
| MAPE | Mean absolute percentage error | 0.0739 |
| SAE | Sum of the absolute errors | 10.575 |
Predictive Modules for Dermata Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Dermata Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Dermata Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Dermata Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Dermata Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Dermata Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Dermata Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Dermata Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Dermata Therapeutics' historical news coverage. Dermata Therapeutics' after-hype downside and upside margins for the prediction period are 0.10 and 11.97, respectively. We have considered Dermata Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Dermata Therapeutics is dangerous at this time. Analysis and calculation of next after-hype price of Dermata Therapeutics is based on 3 months time horizon.
Dermata Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Dermata Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dermata Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Dermata Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.27 | 9.99 | 0.04 | 0.05 | 9 Events / Month | 5 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
2.02 | 1.98 | 1.98 |
|
Dermata Therapeutics Hype Timeline
Dermata Therapeutics is currently traded for 2.02. The entity has historical hype elasticity of -0.04, and average elasticity to hype of competition of -0.05. Dermata is expected to decline in value after the next headline, with the price expected to drop to 1.98. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -1.98%, whereas the daily expected return is currently at -0.27%. The volatility of related hype on Dermata Therapeutics is about 5102.15%, with the expected price after the next announcement by competition of 1.97. About 42.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.61. Some equities with similar Price to Book (P/B) outperform the market in the long run. Dermata Therapeutics recorded earning per share (EPS) of 15.24. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 1st of August 2025. Given the investment horizon of 90 days the next expected press release will be in about 9 days. Check out Historical Fundamental Analysis of Dermata Therapeutics to cross-verify your projections.Dermata Therapeutics Related Hype Analysis
Having access to credible news sources related to Dermata Therapeutics' direct competition is more important than ever and may enhance your ability to predict Dermata Therapeutics' future price movements. Getting to know how Dermata Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Dermata Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ATXI | Avenue Therapeutics | (2.75) | 19 per month | 0.00 | (0.19) | 12.66 | (20.69) | 50.24 | |
| WINT | Windtree Therapeutics | 0.00 | 6 per month | 0.00 | (0.24) | 16.67 | (20.00) | 58.33 | |
| CARM | Carisma Therapeutics | 0 | 5 per month | 9.24 | 0 | 18.00 | (14.06) | 56.42 | |
| PBM | Psyence Biomedical Ltd | 0.03 | 9 per month | 14.50 | 0.07 | 12.65 | (13.79) | 96.66 | |
| LIPO | Lipella Pharmaceuticals Common | 0.03 | 19 per month | 0.00 | (0.02) | 17.14 | (16.00) | 44.95 | |
| VRAX | Virax Biolabs Group | 0.01 | 7 per month | 0.00 | (0.07) | 7.89 | (10.20) | 92.80 | |
| ELAB | Elevai Labs Common | 0.64 | 3 per month | 0.00 | (0.38) | 5.71 | (14.29) | 38.62 | |
| GTBP | GT Biopharma | 0.03 | 9 per month | 0.00 | (0.02) | 10.84 | (11.96) | 51.03 | |
| REVB | Revelation Biosciences | 0.08 | 7 per month | 0.00 | (0.24) | 6.12 | (9.09) | 35.57 | |
| ARTL | Artelo Biosciences | (0.03) | 9 per month | 0.00 | (0.09) | 7.86 | (11.25) | 43.34 |
Other Forecasting Options for Dermata Therapeutics
For every potential investor in Dermata, whether a beginner or expert, Dermata Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Dermata Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Dermata. Basic forecasting techniques help filter out the noise by identifying Dermata Therapeutics' price trends.Dermata Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dermata Therapeutics stock to make a market-neutral strategy. Peer analysis of Dermata Therapeutics could also be used in its relative valuation, which is a method of valuing Dermata Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Dermata Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Dermata Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Dermata Therapeutics shares will generate the highest return on investment. By undertsting and applying Dermata Therapeutics stock market strength indicators, traders can identify Dermata Therapeutics entry and exit signals to maximize returns.
| Rate Of Daily Change | 0.9 | |||
| Day Median Price | 2.02 | |||
| Day Typical Price | 2.02 | |||
| Price Action Indicator | (0.11) | |||
| Period Momentum Indicator | (0.23) | |||
| Relative Strength Index | 45.04 |
Dermata Therapeutics Risk Indicators
The analysis of Dermata Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Dermata Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting dermata stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 6.48 | |||
| Standard Deviation | 9.72 | |||
| Variance | 94.57 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Dermata Therapeutics
The number of cover stories for Dermata Therapeutics depends on current market conditions and Dermata Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Dermata Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Dermata Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Dermata Therapeutics Short Properties
Dermata Therapeutics' future price predictability will typically decrease when Dermata Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Dermata Therapeutics often depends not only on the future outlook of the potential Dermata Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Dermata Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 153 K | |
| Cash And Short Term Investments | 3.2 M |
Check out Historical Fundamental Analysis of Dermata Therapeutics to cross-verify your projections. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. Projected growth potential of Dermata fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Dermata Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Dermata Therapeutics's market price often diverges from its book value, the accounting figure shown on Dermata's balance sheet. Smart investors calculate Dermata Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Dermata Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Dermata Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dermata Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.